ACHL News and Press, Achilles Therapeutics plc From 04/25/23

- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor - - Patent applies to any modality, including vaccine and autologous T cell therapy - LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles The...

LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, and Dr. Ed Samuel, EVP, Technical Ope...

2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...

2023-03-15 13:49:35 ET The following slide deck was published by Achilles Therapeutics plc in conjunction with this event. For further details see: Achilles Therapeutics PLC (ACHL) Investor Presentation - Slideshow

2023-03-07 07:51:25 ET Achilles Therapeutics press release ( NASDAQ: ACHL ): Q4 GAAP EPS of -$0.61 misses by $0.39 . Cash and cash equivalents were $173.3 million as of December 31, 2022, as compared to $266.3 million as of December 31, 2021. the Company antic...

- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients - - Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens - - Strong cash position of $173.3 million supports...

Summary I explain why I've added Organigram to my tax loss selling basket. I also review the company's performance and risks. Finally, I recap my entire 2022 tax loss selling basket of stocks, some of which I didn't have time to write up individually. Tax Loss Selling Strategy...

LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41 st Annual J...

- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability profile potentially expands opportunity to include patients ineligible for high dose lymphodep...

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable respons...